The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer.
 
Laura Williams Goff
Consulting or Advisory Role - Celgene
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Lilly; Onyx; Pfizer; Sun Pharma
 
Nilofer Saba Azad
Honoraria - Bayer/Onyx
Consulting or Advisory Role - Dava Oncology
Research Funding - Agios (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Genentech (Inst); Kinex (Inst); Precision Biologics (Inst)
 
Stacey Stein
No Relationships to Disclose
 
Jennifer Whisenant
Patents, Royalties, Other Intellectual Property - Anasys Instruments
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical
 
Roisin M. Connolly
Research Funding - Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - Novartis
 
Amy M. Weise
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Celldex (Inst); EMD Serono (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Patricia LoRusso
Leadership - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech/Roche; Novartis
Honoraria - Genentech/Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; Astellas Pharma; Astex Pharmaceuticals; Boehringer Ingelheim; Genentech; Novartis; Pfizer
Speakers' Bureau - Genentech
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer; Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Wael El-Rifai
No Relationships to Disclose
 
Jordan Berlin
Consulting or Advisory Role - Aduro Biotech; ARMO BioSciences; Boston Biomedical; Celgene; Cornerstone Pharmaceuticals; EMD Serono; Exelixis; Five Prime Therapeutics; Genentech/Roche; Janssen Oncology; Opsona Therapeutics; Pharmacyclics; Pierre Fabre; Symphony Evolution; Vertex
Research Funding - Abbvie (Inst); Bayer (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Loxo (Inst); Merrimack (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Symphony Evolution (Inst); Taiho Pharmaceutical (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Boston Biomedical; Celgene; Genentech/Roche; Janssen Oncology; vertex
Other Relationship - AstraZeneca; Momenta Pharmaceuticals; Symphony Evolution